AU Patent

AU2024310564A1 — Modular multiplatform system for mrna drug production

Assigned to Biontech SE · Expires 2025-11-27 · 0y expired

What this patent protects

A drug production facility includes: a first module comprising drug substance and drug product manufacturing equipment including equipment for producing RNA-based drug substance, lipid nanoparticle (LNP)-based drug products and lipoplex-based drug products; and a second module th…

USPTO Abstract

A drug production facility includes: a first module comprising drug substance and drug product manufacturing equipment including equipment for producing RNA-based drug substance, lipid nanoparticle (LNP)-based drug products and lipoplex-based drug products; and a second module that includes fill and finish process equipment.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024310564A1
Jurisdiction
AU
Classification
—
Expires
2025-11-27
Drug substance claim
No
Drug product claim
No
Assignee
Biontech SE
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.